4 patents currently held
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2033. from the record
Of the 11 now held by other companies, 11 name Emboline Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2033
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Nov 2033 · Medium confidence
Also notable
Ends Feb 2035 · High confidence
Embolic Protection Device And Method
US 11,446,132
The most cited patent in this portfolio, cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2033. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Device And Method For Delivery Of Medical Devices To A Cardiac Valve
US 11,992,398
Granted 2024. Too new for citation comparison; protection runs to 2035.
Formerly held, still cited
Notable
Ends May 2032 · High confidence
The most cited patent in this portfolio, cited by 95 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2032.
now held by Emboline, Inc.
Also notable
Ends May 2035 · High confidence
Cited by 59 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Emboline, Inc.
Also notable
Ends Sep 2029 · High confidence
Cited by 27 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2029.
now held by Emboline, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 16, 2027The maintenance fee for Embolic Protection Device And Method (US 11,957,561) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Embolic Protection Device And Method (2022) | 2 in force | to May 2035 |
| Device And Method For Delivery Of Medical Devices To A Cardiac Valve | 1 in force | to Feb 2035 |
| Embolic Protection Device And Method (2018) | 1 in force | to Nov 2033 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,446,132 | Embolic Protection Device And Method In force · Medium confidence | In force | Medium confidence | |
| US 11,992,398 | Device And Method For Delivery Of Medical Devices To A Cardiac Valve In force · High confidence | In force | High confidence | |
| US 11,957,561 | Embolic Protection Device And Method held by Emboline, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 12,472,051 | Embolic Protection Device and Method held by Emboline, Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 11 patents in force now held by others · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed